Table 3.
Prostate cancer risk by genotypes of estrogen-related genes and serum cholesterol and hormone levels in the placebo arm in the PCPT
| Gene | SNP | Genotype | Controls | Cases | ORa (95% CI) | Controls | Cases | ORa (95% CI) | P for interaction |
|---|---|---|---|---|---|---|---|---|---|
| Cholesterol < median (206 mg/dl) | Cholesterol ≥ median (206 mg/dl) | ||||||||
| ESR1 | rs1801132b | CC | 246 | 233 | 1.00 | 238 | 300 | 1.00 | 0.17 |
| CG | 155 | 123 | 0.84 (0.62–1.13) | 155 | 155 | 0.79 (0.60–1.05) | |||
| GG | 18 | 21 | 1.24 (0.64–2.39) | 31 | 21 | 0.54 (0.30–0.96) | |||
| CG/GG | 173 | 144 | 0.88 (0.66–1.17) | 186 | 176 | 0.75 (0.57–0.98) | |||
| CYP19A1 | rs2445765 | GG | 266 | 274 | 1.00 | 298 | 330 | 1.00 | 0.13 |
| CG | 135 | 97 | 0.70 (0.51–0.95) | 111 | 132 | 1.07 (0.80–1.44) | |||
| CC | 16 | 12 | 0.72 (0.34–1.56) | 11 | 13 | 1.08 (0.48–2.44) | |||
| CG/CC | 151 | 109 | 0.70 (0.52–0.94) | 122 | 145 | 1.07 (0.81–1.43) | |||
| CYP19A1 | rs700519 | CC | 404 | 353 | 1.00 | 398 | 447 | 1.00 | 0.22 |
| CT | 18 | 29 | 1.84 (1.00–3.36) | 25 | 31 | 1.10 (0.64–1.90) | |||
| TT | N/A | N/A | |||||||
| CYP1B1 | rs10012 | CC | 161 | 149 | 1.00 | 190 | 175 | 1.00 | 0.17 |
| CG | 132 | 109 | 0.90 (0.64–1.26) | 115 | 128 | 1.21 (0.87–1.67) | |||
| GG | 27 | 22 | 0.88 (0.48–1.62) | 22 | 36 | 1.79 (1.01–3.16) | |||
| Testosterone < median (358 ng/dl) | Testosterone ≥ median (358 ng/dl) | ||||||||
| ESR1 | rs1801132b | CC | 220 | 250 | 1 | 257 | 288 | 1 | 0.10 |
| CG | 165 | 136 | 0.72 (0.54–0.97) | 145 | 143 | 0.88 (0.66–1.17) | |||
| GG | 31 | 17 | 0.48 (0.26–0.89) | 18 | 24 | 1.20 (0.64–2.26) | |||
| CG/GG | 196 | 153 | 0.69 (0.52–0.91) | 163 | 167 | 0.91 (0.69–1.20) | |||
| CYP1B1 | rs1800440 | AA | 272 | 267 | 1.00 | 277 | 316 | 1.00 | 0.15 |
| AG | 123 | 128 | 1.06 (0.78–1.43) | 130 | 129 | 0.87 (0.65–1.17) | |||
| GG | 19 | 8 | 0.43 (0.19–1.00) | 10 | 13 | 1.14 (0.49–2.63) | |||
| AG/GG | 142 | 136 | 0.98 (0.73–1.30) | 140 | 142 | 0.89 (0.67–1.18) | |||
| UGT1A6 | rs4124874 | AA | 102 | 91 | 1.00 | 113 | 95 | 1.00 | 0.57 |
| AC | 168 | 162 | 1.08 (0.76–1.54) | 140 | 166 | 1.41 (0.99–2.01) | |||
| CC | 60 | 50 | 0.94 (0.59–1.50) | 69 | 68 | 1.17 (0.76–1.80) | |||
| Estradiol < median (32.2 pg/ml) | Estradiol ≥ median (32.2 pg/ml) | ||||||||
| HSD17B2 | rs4445895 | CC | 151 | 130 | 1.00 | 117 | 125 | 1.00 | <0.01 |
| CT | 140 | 142 | 1.19 (0.85–1.66) | 151 | 152 | 0.94 (0.67–1.32) | |||
| TT | 35 | 49 | 1.64 (1.00–2.69) | 56 | 33 | 0.55 (0.33–0.91) | |||
| CYP19A1 | rs700518 | GG | 112 | 93 | 1.00 | 112 | 127 | 1.00 | 0.03 |
| AG | 189 | 230 | 1.47 (1.05–2.05) | 217 | 207 | 0.84 (0.61–1.16) | |||
| AA | 107 | 96 | 1.08 (0.73–1.59) | 84 | 95 | 1.00 (0.68–1.47) | |||
| CYP1B1 | rs1800440 | AA | 277 | 292 | 1.00 | 272 | 289 | 1.00 | 0.11 |
| AG | 122 | 130 | 1.01 (0.75–1.36) | 131 | 127 | 0.91 (0.68–1.23) | |||
| GG | 15 | 5 | 0.32 (0.11–0.88) | 14 | 16 | 1.08 (0.52–2.25) | |||
| AG/GG | 137 | 135 | 0.93 (0.70–1.25) | 145 | 143 | 0.93 (0.70–1.23) | |||
| UGT1A6 | rs4124874 | AA | 95 | 98 | 1.00 | 120 | 88 | 1.00 | 0.22 |
| AC | 166 | 168 | 0.98 (0.69–1.40) | 142 | 158 | 1.52 (1.07–2.17) | |||
| CC | 61 | 55 | 0.87 (0.55–1.38) | 68 | 63 | 1.27 (0.82–1.97) | |||
| UGT2B7 | rs7439366 | TT | 77 | 86 | 1.00 | 93 | 74 | 1.00 | 0.03 |
| TC | 165 | 173 | 0.94 (0.65–1.37) | 164 | 139 | 1.07 (0.73–1.56) | |||
| CC | 74 | 59 | 0.71 (0.45–1.13) | 67 | 84 | 1.59 (1.02–2.47) | |||
| Estrone < median (42.1 pg/ml) | Estrone ≥ median (42.1 pg/ml) | ||||||||
| UGT1A6 | rs4124874 | AA | 97 | 89 | 1.00 | 116 | 97 | 1.00 | 0.40 |
| AC | 157 | 147 | 1.02 (0.71–1.47) | 147 | 176 | 1.44 (1.02–2.04) | |||
| CC | 64 | 57 | 0.97 (0.61–1.54) | 65 | 61 | 1.12 (0.72–1.74) | |||
| UGT1A10 | rs2741049 | TT | 127 | 108 | 1.00 | 113 | 138 | 1.00 | 0.07 |
| TC | 138 | 124 | 1.06 (0.74–1.51) | 137 | 129 | 0.77 (0.55–1.10) | |||
| CC | 48 | 54 | 1.32 (0.83–2.11) | 70 | 54 | 0.63 (0.41–0.97) | |||
Bold values indicate significant/borderline significant findings.
a
Adjusted for age and family history.
b
Significant SNPs identified in overall analyses.